Treatment for 2 mo with n 3 polyunsaturated fatty acids reduces adiposity and some atherogenic factors but does not improve insulin sensitivity in women with type 2 diabetes: a randomized controlled study.
Treatment for 2 mo with n 3 polyunsaturated fatty acids reduces adiposity and some atherogenic factors but does not improve insulin sensitivity in women with type 2 diabetes: a randomized controlled study.
复制标题
DOI：
10.1093/ajcn/86.5.1670
复制
发表时间：
2007-12
期刊：
影响因子：
--
通讯作者：
M. Kabir;G. Skurnik;Nadia Naour;V. Pechtner;E. Meugnier;S. Rome;A. Quignard‐Boulangé;H. Vidal;G. Slama;K. Clément;M. Guerre-Millo;S. Rizkalla
中科院分区：
文献类型：
--
作者：
M. Kabir;G. Skurnik;Nadia Naour;V. Pechtner;E. Meugnier;S. Rome;A. Quignard‐Boulangé;H. Vidal;G. Slama;K. Clément;M. Guerre-Millo;S. Rizkalla
关于n-3多不饱和脂肪酸（PUFAs）对2型糖尿病患者脂肪组织的潜在影响，目前缺乏相关信息。目的：我们评估n-3 PUFAs是否对2型糖尿病患者的肥胖、胰岛素敏感性、脂肪组织功能（脂肪因子、炎症和动脉粥样硬化因子的产生）和基因表达有额外的影响。设计：27名无高甘油三酯血症的2型糖尿病女性在双盲平行设计中随机分配至3 g/d鱼油（1.8 g n-3 PUFAs）或安慰剂（石蜡油）2个月。结果：虽然使用食物日记测量的体重和能量摄入没有变化，但鱼油组的总脂肪量（P < 0.019）和皮下脂肪细胞直径（P < 0.0018）低于安慰剂组。胰岛素敏感性在两组之间无显著差异（所有患者通过体内平衡模型评估和每组5例患者的正糖-高胰岛素钳亚组测量）。相比之下，鱼油组的动脉粥样硬化危险因素，包括血浆甘油三酯（P < 0.03）、甘油三酯与高密度脂蛋白胆固醇之比（动脉粥样硬化指数，P < 0.03）和血浆纤溶酶原激活物抑制剂-1 (P < 0.01)，均低于安慰剂组。此外，鱼油治疗后皮下脂肪组织中的炎症相关基因亚群减少，而安慰剂治疗后则没有。结论：在2型糖尿病患者中，中等剂量的n-3 PUFAs治疗2个月可降低肥胖和动脉粥样硬化标志物，而不会使胰岛素敏感性恶化。一些脂肪组织炎症相关基因也减少了。这些有益作用可能与脂肪组织的形态和炎症变化有关。该试验在clinicaltrials.gov注册为NCT0037。
BACKGROUND Information is lacking on the potential effect of n-3 polyunsaturated fatty acids (PUFAs) on the adipose tissue of patients with type 2 diabetes. OBJECTIVE We evaluated whether n-3 PUFAs have additional effects on adiposity, insulin sensitivity, adipose tissue function (production of adipokines and inflammatory and atherogenic factors), and gene expression in type 2 diabetes. DESIGN Twenty-seven women with type 2 diabetes without hypertriglyceridemia were randomly allocated in a double-blind parallel design to 2 mo of 3 g/d of either fish oil (1.8 g n-3 PUFAs) or placebo (paraffin oil). RESULTS Although body weight and energy intake measured by use of a food diary were unchanged, total fat mass (P < 0.019) and subcutaneous adipocyte diameter (P < 0.0018) were lower in the fish oil group than in the placebo group. Insulin sensitivity was not significantly different between the 2 groups (measured by homeostasis model assessment in all patients and by euglycemic-hyperinsulinemic clamp in a subgroup of 5 patients per group). By contrast, atherogenic risk factors, including plasma triacylglycerol (P < 0.03), the ratio of triacylglycerol to HDL cholesterol (atherogenic index, P < 0.03), and plasma plasminogen activator inhibitor-1 (P < 0.01), were lower in the fish oil group than in the placebo group. In addition, a subset of inflammation-related genes was reduced in subcutaneous adipose tissue after the fish oil, but not the placebo, treatment. CONCLUSIONS A moderate dose of n-3 PUFAs for 2 mo reduced adiposity and atherogenic markers without deterioration of insulin sensitivity in subjects with type 2 diabetes. Some adipose tissue inflammation-related genes were also reduced. These beneficial effects could be linked to morphologic and inflammatory changes in adipose tissue. This trial was registered at clinicaltrials.gov as NCT0037.